Bambusa Therapeutics Completes Patient Enrollment in the Phase 1b/2a Trial Evaluating BBT001 as a Treatment for Atopic...

IQM and Real Asset Acquisition Corp. Announce Public Filing of Form F-4 Registration Statement with the...

Weitere Details unter: https://www.prnewswire.com/news-releases/bambusa-therapeutics-raises-approximately-90-million-in-series-a-financing-to-advance-next-generation-bispecific-antibodies-for-immunology–inflammation-diseases-302376866.html

Weitere Details finden Sie unter: https://inplanet.earth/press/worlds-first-enhanced-rock-weathering-carbon-removal-credits-issued/

Weitere Details unter: https://www.prnewswire.com/news-releases/bambusa-therapeutics-inc-announces-successful-series-seed-funding-to-advance-innovative-bispecific-antibodies-for-immunology–inflammation-302241958.html?tc=eml_cleartime

Weitere Details unter: https://onedata.ai/one-data-closes-eur-32-million-series-b-extension/

Weitere Informationen finden Sie hier: Artikel BUSINESS INSIDER